The increase in Journey Medical’s consensus analyst price target to $10.50 reflects improved future earnings expectations as indicated by a higher forward P/E, despite a slight decline in net profit margin.
What's in the News
- Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), Journey Medical’s treatment for inflammatory rosacea lesions in adults, now has pharmacy benefit coverage for 65% of U.S. commercial lives, up from 29% in May.
- Phase 3 trial data for Emrosi™ showed efficacy was not impacted by patient body weight, supporting its FDA approval, and results will be presented at the SDPA 2025 Summer Dermatology Conference.
- Journey Medical was added to multiple Russell indexes, including the Russell 2000, 2500, 3000, Small Cap Completeness, and associated Growth and Dynamic sub-indices.
- At its recent annual meeting, Journey Medical approved the Fourth Amended and Restated Charter to include officer exculpation provisions.
Valuation Changes
Summary of Valuation Changes for Journey Medical
- The Consensus Analyst Price Target has risen from $9.75 to $10.50.
- The Future P/E for Journey Medical has significantly risen from 5.31x to 6.15x.
- The Net Profit Margin for Journey Medical has fallen from 34.82% to 33.03%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.